For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...
Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...
– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
Molecular testing practice patterns for lung cancer based on gender: Insights into disparities and opportunities for precision medicine. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in median progression-free survival (PFS) by 2.9 months compared to fulvestrant in patients with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results